Skip to main content
SpringerLink
Log in

Clinical implications of multidrug resistance to chemotherapy

  • Chapter
Molecular and Clinical Advances in Anticancer Drug Resistance

Part of the book series: Cancer Treatment and Research ((CTAR,volume 57))

Abstract

One of the major problems in clinical oncology is the existence or development of drug resistance. Improvement of therapeutic modalities will only be possible with better understanding of mechanisms of drug resistance and identification of resistant tumor cells in human tumors. With this knowledge special treatments in case of drug resistance should be developed. Tumors with intrinsic (de novo) resistance, known to be refractory to chemotherapy at initial diagnosis are, for example, colon carcinomas, adenocarcinomas of the lung, and melanomas. Other tumors respond initially, but later on show acquired resistance. This is illustrated by the clinical course of small-cell lung carcinomas and acute myeloid leukemias. Initially, a high remission percentage is found, but often relapses occur within 1-2 years. Subsequent attempts to obtain remission induction either fail, or the results are incomplete and remissions are nearly always of shorter duration.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Deffie, A.M., Batra, J.K., and Goldenberg, GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and-resistant P388 leukemia cell lines. Cancer Res. 49:58–62, 1989.

    PubMed  CAS  Google Scholar 

  2. Deffie, A.M., Alam, T., Seneviratne, C, Beenken, S.W., Batra, J.K., Shea, T.C., Henner, W.D., and Goldenberg, G.J. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res. 48:3595–3602, 1988.

    PubMed  CAS  Google Scholar 

  3. Sinha, B.K., Haim, N., Dusre, L., Kerrigan, D., and Pommier, Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 48:5096–5100, 1988.

    PubMed  CAS  Google Scholar 

  4. Batist, G., Tulpule, A., Sinha, B.K., Katki, A.G., Myers, C.E., and Cowan, K.H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem. 261:15544–15549, 1986.

    PubMed  CAS  Google Scholar 

  5. Ido, M., Sato, K., Sakurai, M., Inagaki, M., Saitoh, M., Watanabe, M., and Hidaka, H. Decreased phorbol ester receptor and protein kinase C in P388 murine leukemic cells resistant to etoposide. Cancer Res. 47:3460–3463, 1987.

    PubMed  CAS  Google Scholar 

  6. Fine, R.L., Platel, J., and Chabner, B.A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA 85:582–586, 1988.

    Article  PubMed  CAS  Google Scholar 

  7. De Vries, E.G.E., Meijer, C., Timmer-Bosscha, H., Berendsen, H.H., de Ley, L., Scheper, R.J., and Mulder, N.H. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res. 49:4175–4178, 1989.

    PubMed  Google Scholar 

  8. Shen, D.W., Fojo, A., Chin, J.E., Roninson, I.B., Richert, N., Pastan, I., and Gottesman, M.M. Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 232:643–645, 1986.

    Article  PubMed  CAS  Google Scholar 

  9. Bradley, G., Naik, M., and Ling, V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res. 49:2790–2796, 1989.

    PubMed  CAS  Google Scholar 

  10. Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., and Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA 84:265–269, 1987.

    Article  PubMed  CAS  Google Scholar 

  11. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., and Willingham, M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735–7738, 1987.

    Article  PubMed  CAS  Google Scholar 

  12. Van der Valk, P., van Kalken, C.K., Ketelaars, H., Broxterman, H J., Scheffer, G.L., Kuiper, C M., Tsuruo, T., Lankelma, J., Meyer, C.J.L.M., Pinedo, H.M., and Scheper, R. J. Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue. Ann. Oncol. 1:56–64, 1990.

    PubMed  Google Scholar 

  13. Goldstein, L.J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gadzdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G.M., Lieber, M., Cossman, J., Gottesman, M.M., and Pastan, I. Expression of a multidrug resistant gene in human cancers. J. Natl. Cancer Inst. 81:116–124, 1989.

    Article  PubMed  CAS  Google Scholar 

  14. Bell, D.R., Gerlach, J.H., Kartner, N., Buick, R.N., and Ling, V. Detection of P-glycoprotein in ovarian cancer; a molecular marker associated with drug resistance. J. Clin. Oncol. 3:311–315, 1985.

    PubMed  CAS  Google Scholar 

  15. Holmes, J., Jacobs, A., Carter, G., Janouski-Wieczorek, A., and Padua, R.A. Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br. J. Haematol. 72:40–44, 1989.

    Article  PubMed  CAS  Google Scholar 

  16. Epstein, J., Xiao, H., and Oba, B.K. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood 74:913–917, 1989.

    PubMed  CAS  Google Scholar 

  17. Bourhus, J., Goldstein, L.J., Riou, G., Pastan, I., Gottesman, M.M., and Bénard, J. Expression of a human multidrug resistance gene in ovarian carcinoma. Cancer Res. 49:5062–5096, 1989.

    Google Scholar 

  18. Rothenberg, M., Mickley, L., Cole, D.E., Balis, F.M., Tsuruo, T., Poplack, D.G., and Fojo, A.T. Expression of the mdr-l/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388–1395, 1989.

    PubMed  CAS  Google Scholar 

  19. Gerlach, J.H., Bell, D.R., Karakousis, C, Slocum, A.K., Kartner, N., Rustum, Y.M., Ling, V., and Baker, R.M. P-glycoprotein in human sarcoma, evidence for multidrug resistance. J. Clin. Oncol. 5:1452–1460, 1987.

    PubMed  CAS  Google Scholar 

  20. Ma, D.D.F., Davey, R.A., Harman, D.H., Isbister, J.P., Scurr, R.D., Mackertich, S.M., Dowden, G., and Bell, D.R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. Lancet 1:135–137, 1987.

    Article  PubMed  CAS  Google Scholar 

  21. Lai, S.-L., Goldstein, L.J., Gottesman, M.M., Pastan, I., Tsai, C, Johnson, B.E., Mulshine, J.L., Ihde, D.C., Kayser, K., and Gazdar, A.F. MDR1 gene expression in lung cancer. J. Natl. Cancer Inst. 81:1144–1150, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Merkel, D.E., Fuquo, S.A.W., Tandon, A.K., Hill, S.M., Buzdar, A.U., and McGuire, W.L. Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J. Clin. Oncol. 7:1129–1136, 1989.

    PubMed  CAS  Google Scholar 

  23. Salman, S.E., Grogan, T.M., Miller, T., Scheper, R., and Dalton, W.S. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J. Natl. Cancer Inst. 81:696–701, 1989.

    Article  Google Scholar 

  24. Kacinski, B.M., Yee, L.D., and Carter, D. Quantitation of tumor cell expression of the P-glycoprotein (mdrl) gene in human breast carcinoma clinical specimens. Cancer Bull. 41:44–48, 1989.

    Google Scholar 

  25. Shen, D.-W., Pastan, I., and Gottesman, M.M. In situ hybridization analysis of acquisition and loss of the human multidrug resistance gene. Cancer Res. 48:4334–4339, 1988.

    PubMed  CAS  Google Scholar 

  26. Dalton, W.S., Grogan, T.M., Rybski, J.A., Scheper, R.J., Richter, L., Kailey, J., Broxterman, H.J., Pinedo, H.M., and Salmon, S.E. Immunohistochemical detection and quantitation of P-glycoprotein in multidrug resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73:747–752, 1989.

    PubMed  CAS  Google Scholar 

  27. Wooten, P., Cuddy, D., Felsted, P., Pan, S., and Ross, D. Comparison of anti-P-glycoprotein monoclonal antibodies MRK16, 265/F4 and C219 in the detection of multidrug resistant cells. Proc. Am. Assoc. Cancer Res. 30:2105, 1989.

    Google Scholar 

  28. Scheper, R.J., Bulte, J.W.M., Brakkee, J.G.P., Quak, J.J., van der Schoot, E., Balm, A.J.M., Meyer, C.J.L.M., Broxterman, H.J., Kuiper, CM., Lankelma, J., and Pinedo, H.M. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int. J. Cancer 42:389–394, 1988.

    Article  PubMed  CAS  Google Scholar 

  29. Nooter, K., Herweyer, H., Sonneveld, P., Verwey, J., Hagenbeek, A., and Stoter, G. Detection of multidrug resistance in refractory cancer patients (obstr.). Proc. Am. Assoc. Cancer Res. 30:2092, 1989.

    Google Scholar 

  30. Marayana, Y., Murohashi, I., Nara, N., and Aoki, N. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia. Br. J. Haematol. 72:357–362, 1989.

    Article  Google Scholar 

  31. Dalton, W.S., Grogan, T.M., Meltzer, P.S., Scheper, R.J., Durie, B.G.M., Taylor, C.W., Miller, T.P., and Salmon, S.E. Drug-resistance in multiple myeloma and non-Hodgkin’ s lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7:415–424, 1989.

    PubMed  CAS  Google Scholar 

  32. Preisler, H.D., Gottesman, M., Raza, A., Pastan, I., and Day, R. The clinical significance of expression of the multidrug resistance (MDR) gene in acute nonlymphocytic leukemia (ANLL).Proc. ASCO 8:782, 1989.

    Google Scholar 

  33. Keizer, H.G., Schuurhuis, G.J., Broxterman, H.J., Lankelma, J., Schoonen, W.G.E.J., van Rijn, J., Pinedo, H.M., and Joenje, H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 49: 2988–2993, 1989.

    PubMed  CAS  Google Scholar 

  34. Schuurhuis, G.J., Broxterman, H.J., Cervantes, A., Van Heyningen, T.H., De Lange J.H., Baak, J.D., and Pinedo, H.M. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J. Natl. Cancer Inst. 81:1887–1892, 1989.

    Article  PubMed  CAS  Google Scholar 

  35. Hindenburg, A.A., Gervasoni, J.E., Krishna, S., Stewart, V.J., Rosado, M., Lutzky, J., Bhalla, K., Baker, M.A., and Taub, R.N. Intracellular distribution and pharmacokinetics of daunorubicin in antracylcine-sensitive and-resistant HL-60 cells. Cancer Res. 49: 4607–4614, 1989.

    PubMed  CAS  Google Scholar 

  36. Dorr, R.T., Liddil, J.D., Trent, J.M., and Dalton, W.S. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem. Pharmacol. 36: 3115–3120, 1987.

    Article  PubMed  CAS  Google Scholar 

  37. Beck-Hansen, N.T., Till, J.E., and Ling, V. Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J. Cell Physiol. 88:23–32, 1976.

    Article  Google Scholar 

  38. Cantwell, B.M.J., Bozzino, J.M., Corris, P., and Harris, A.L. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP 16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. Eur. J. Cancer Clin. Oncol. 24:123–129, 1988.

    Article  PubMed  CAS  Google Scholar 

  39. Nakagawa, M., Akiyama, S., Yamaguchi, T., Shiraishi, N., Ogata, J., and Kuwano, M. Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line. Cancer Res. 46:4453–4457, 1986.

    PubMed  CAS  Google Scholar 

  40. Zamora, J.M., Pearce, H.L., and Beck, W.T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 33:454–462, 1988.

    PubMed  CAS  Google Scholar 

  41. Pearce, H.L., Safa, A.R., Bach, N.J., Winter, M.A., Cirtain, M.C., and Beck, W.T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. 86:5128–5132, 1989.

    Article  PubMed  CAS  Google Scholar 

  42. Akiyama, S.-I., Cornwell, M.M., Kuwano, M., Pastan, I., and Gottesman, M.M. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol. Pharmacol. 34:180–185, 1988.

    Google Scholar 

  43. Beek, W.T., Cirtain, M.C., Glover, C.J., et al. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem. Biophys. Res. Commun. 153:959–966, 1988.

    Article  Google Scholar 

  44. Cornwell, M.M., Pastan, I., and Gottesman, M.M. Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J. Biol. Chem. 262:2166–2170, 1987.

    PubMed  CAS  Google Scholar 

  45. Benson, A.B., Trump, D.L., Kodier, J.M., Egorin, M.I., Olman, E.A., Witte, R.S., Davis, T.E., and Tormey, D.C. Phase 1 study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat. Rep. 69:795–799, 1985.

    PubMed  Google Scholar 

  46. Bessho, F., Kinumaki, H., Kobayashi, M., Habu, H., Nakamura, K., Yohata, S., Tsuruo, T., and Kobayashi, N. Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem. Med. Ped. Oncol. 13:199–202, 1985.

    Article  CAS  Google Scholar 

  47. Rogan, A.M., Hamilton, T.C., Young, R.C., Klecker, R.W., and Ozols, R.F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994–996, 1984.

    Article  PubMed  CAS  Google Scholar 

  48. Ozols, R.F., Cunnion, R.E., Klecker, R.W., Hamilton, T.C., Ostchega, Y., Parrillo, J.E., and Young, R.C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J. Clin. Oncol. 5:641–647, 1987.

    PubMed  CAS  Google Scholar 

  49. Louie, K.G., Hamilton, T.C., and Winker, M.A. Adriamycin accumulation and metabolism in adriamycin-sensitive and resistant human ovarian cancer cell lines. Biochem. Pharmacol. 35:467–472, 1986.

    Article  PubMed  CAS  Google Scholar 

  50. Fojo, A., Hamilton, T.C., Young, R.C, and Ozols, R.F. Multidrug resistance in ovarian cancer. Cancer 60:2075–2080, 1987.

    Article  PubMed  CAS  Google Scholar 

  51. Durie, B.G.M. and Dalton, W.S. Reversal of drug-resistance in multiple myeloma with verapamil. Br. J. Haematol. 68:203–206, 1988.

    Article  PubMed  CAS  Google Scholar 

  52. Fine, R.L., Koizumi, S., Curt, G.A., and Chabner, B.A. Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs, J. Clin. Oncol. 5:489–495, 1987.

    CAS  Google Scholar 

  53. Benet, L.Z. Pharmacokinetics and metabolism of bepridil. Am. J. Cardiol. 55:8C–13C, 1985.

    Article  PubMed  CAS  Google Scholar 

  54. Schuurhuis, G.J., Broxterman, H.J., van der Hoeven, J.J.M., Pinedo, H.M., and Lankelma, J. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in antracycline-resistant and-sensitive cell lines. Cancer Chemother. Pharmacol. 20:285–290, 1987.

    Article  PubMed  CAS  Google Scholar 

  55. Van der Hoeven, J.J.M., van Kalken, C.K., Maessen, P., van der Vijgh, W.J.F., and Pinedo, H.M. Combination of doxorubicin (Dox) and the calcium channel blocker bepridil (Bp) in patients with Dox resistant tumors,. In: 5th European Conference on Clinical Oncology (abstr. no O-0428) 1989.

    Google Scholar 

  56. Formelli, F., Cleris, L., and Carsana, R. Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. Cancer Chemother. Pharmacol. 21:329–336, 1988.

    CAS  Google Scholar 

  57. Hait, W.N. and Lazo, J.S. Calmodulin: a potential target for cancer chemotherapeutic agents. J. Clin. Oncol. 4:994–1012, 1986.

    PubMed  CAS  Google Scholar 

  58. Miller R.L., Bukowski, R.M., Budd, T., Purvis, J., Weick, J.K., Shepard, K., Midha, K.K., and Ganapathi, R. Clinical modulation of doxorubicin resistance by the cadmodulin-inhibitor, trifluoperazine. A phase I/II trial. J. Clin. Oncol. 6:880–888, 1988.

    CAS  Google Scholar 

  59. Fojo, A.T., Shen, D.-W., Mickley, L.A., Pastan, I., and Gottesman, M.M. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Clin. Oncol. 5:1922–1927, 1987.

    PubMed  CAS  Google Scholar 

  60. Chauffert, B., Rey, p., Coudert, B., Duras, M., and Martin, F. Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells. Br. J. Cancer 56:119–122, 1987.

    Article  PubMed  CAS  Google Scholar 

  61. Kanamaru, H., Kakehi, Y., Yoshida, O., Nakanishi, S., Pastan, I., and Gottesman, M.M. MDRl RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor expiants. J. Natl. Cancer Inst. 81:844–849, 1989.

    Article  PubMed  CAS  Google Scholar 

  62. Benet, L.Z. and Williams, R.L. Design and optimization of dosage regimens: pharmaco-kinetic data. In: The Pharmacological Basis of Therapeutics, Goodman Gilman, A., Rail, T.W., Nies, A.S., Taylor, P. (eds.). Pergamon Press, New York, p. 1705, 1990.

    Google Scholar 

  63. Chauffert, B., Martin, M., Hamman, A., Michel, M.F., and Martin, F. Amiodarone-induced enhancement of doxorubicin and 4’-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. Cancer Res. 46:825–830, 1986.

    PubMed  CAS  Google Scholar 

  64. Singh, B.N., Venkatesh, N., Nademanee, K., Josephson, M.A., and Kannan, R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Progress Cardiovasc. Dis. 31:249–281, 1989.

    Article  CAS  Google Scholar 

  65. Fojo, T., McAtee, N., Allegra, C., Bates, S., Mickley, L., Reiser, H., Linehan, M., Steinberg, S., Tucker, E., Goldstein, L., Gottesman, M.M., and Pastan, I. Use of quinidine and amiodarone to modulate multidrug resistance mediated by mdrl gene. Proc. ASCO 8:262. 1989.

    Google Scholar 

  66. Rothenberg, M. and Ling V. Multidrug resistance: molecular biology and clinical relevance. J. Natl. Cancer Inst. 81:907–910, 1989.

    Article  PubMed  CAS  Google Scholar 

  67. Cantwell, B., Carmichael, J., Millward, M, Chatterjee, M., and Harris, A.L. Intermittent high dose tamoxifen with oral etoposide (epo): phase I and II clinical studies. Proc. ASCO 8:252. 1989.

    Google Scholar 

  68. DeGregorio, M.W., Ford, J.M., Benz, C.C., and Wiebe, V.J. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J. Clin. Oncol. 7:1359–1364, 1989.

    Google Scholar 

  69. Hamada, H. and Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 83:7785–7789, 1986.

    Article  PubMed  CAS  Google Scholar 

  70. Broxterman, H.J., Kuiper, CM., Schuurhuis, G.J., Tsuruo, T., Pinedo, H.M., and Lankelma, J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem. Pharmacol. 37:2389–2393, 1988.

    Article  PubMed  CAS  Google Scholar 

  71. FitzGerald, D.J., Willingham, M.C., Cardarelli, CO., Hamada, H., Tsuruo, T., Gottesman, M.M., and Pastan, I. A monoclonal antibody Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 84:4288–4292, 1987.

    Article  PubMed  CAS  Google Scholar 

  72. Hamilton, T.C., Winker, M.A., Konie, K.G., Batist, G., Behrens, B.C., Tsuruo, T., Grotzinger, K.R., McKoy, W.M., Young, R.G., and Ozols, R.F. Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol. 34:2583–2586, 1985.

    Article  PubMed  CAS  Google Scholar 

  73. Dusre, L., Mimnaugh, E.G., Myer, S.C.E., and Sinha, B.K. Potentation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells. Cancer Res. 49:511–515, 1989.

    PubMed  CAS  Google Scholar 

  74. Kramer, R.A., Zakher, J., and Kim, G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241:694–697, 1988.

    Article  PubMed  CAS  Google Scholar 

  75. Moscow, J.A., Fairchild, C.R., Madden, M.J., Ramson, D.T., Wieand, H.S., O’Brien, E.E., Poplack, D.G., Cossman, J., Myers, CE., and Cowan, K.H. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 49:1422–1428, 1989.

    PubMed  CAS  Google Scholar 

  76. Nagourney, R.A., Messenger, J.C., Kern, D.H., and Weisenthal, L.M. In vitro enhancement of doxorubicin (Dox) and nitrogen mustard (NM) cytotoxicity in drug resistant human neoplasms by ethacrynic acid (EA).Proc. Am. Assoc. Cancer Res. 30:2283, 1989.

    Google Scholar 

  77. Epstein, R.J. and Smith, P.J. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res. 48:297–303, 1988.

    PubMed  CAS  Google Scholar 

  78. Alexander, R.B., Nelson, W.G., and Coffey, D.S. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res. 47:2403–2406, 1987.

    PubMed  CAS  Google Scholar 

  79. Zwelling, L.A., Chan, D., Hinds, M., Mayes, J., Silberman, L.E., and Blick, M. Effect of phorbol ester treatment on drug-induced topoisomerase H-mediated DNA cleavage in human leukemia cells. Cancer Res. 48:6625–6633, 1988.

    PubMed  CAS  Google Scholar 

  80. Sahyoun, N., Wolf, M., Besterman, J., Hsieh, T.-S., Sander, M., Le Vine, III H., Chang, K.-J., and Cuatrecasas, P. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc. Natl. Acad. Sci. 83:1603–1607, 1986.

    Article  PubMed  CAS  Google Scholar 

  81. Miskimins, R., Miskimins, W.K., Bernstein, H., and Shimizu, N. Epidermal growth factor-induced topoisomerase(s).Intracellular translocation and relation to DNA synthesis. Exp. Cell Res. 146:53–62, 1983.

    CAS  Google Scholar 

  82. Slevin, M.L., Clark, P.I., Joel, S.P., Malik, S., Osborne, R.J., Gregory, W.M., Lowe, D.G., Reznek, R.H., and Wringley, P.F.M. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7: 1333–1340, 1989.

    PubMed  CAS  Google Scholar 

  83. Hainsworth, J.D., Johnson, D.H., Frazier, S.R., and Greco, F.A. Chronic daily administration of oral etoposide. A phase I trial. J. Clin. Oncol. 7:396–401, 1989.

    CAS  Google Scholar 

  84. Zijlstra, J.G., de Vries, E.G.E., Muskiet, F.A.J., Martini, I.A., Timmer-Bosscha, H., and Mulder, N.H. Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and-resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. J. Cancer 40: 850–856, 1987.

    Article  PubMed  CAS  Google Scholar 

  85. Presant, C.A., Multhauf, P., and Metter, G. Reversal of cancer chemotherapeutic resistance by amphotericin B: a broad based phase I-II pilot study. Eur. J. Cancer Clin. Oncol. 23:683–687, 1987.

    Article  PubMed  CAS  Google Scholar 

  86. Willson, J.K.V., Fisher, P.H., Tutsch, K., Alberti, D., Simon, K., Hamilton, R.D., Bruggink, J., Koeller, J.M., Tormey, D.C., Earhart, R.H., Ranhosky, A., and Trump, D.L. Phase 1 clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res. 48:5585–5590, 1988.

    PubMed  CAS  Google Scholar 

  87. FitzGerald, G.A. Drug therapy: Dipyridamole. N. Engl. J. Med. 20:1247–1257, 1987.

    Google Scholar 

  88. Howell, S.B., Horn, D., Sanga, R., Vick, J.S., and Abramson, I.A. Comparison of the synergistic potentiation of etoposide, doxorubicin and vinblastine cytotoxicity by dipyridamole. Cancer Res. 49:3178–3183, 1989.

    PubMed  CAS  Google Scholar 

  89. Willson, J.K.V., Fisher, P.H., Remick, S.C., Tutsch, K.D., Grem, J.L., Nieting, L., Alberti, D., Bruggink, J., and Trump, D.L. Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res. 49: 1866–1870, 1989.

    PubMed  CAS  Google Scholar 

  90. Chan, T.C.K., Coppoc, G.L., Zimm, S., Cleary, S., and Howell, S.B. Pharmacokinetics of intraperitoneally administered dipyridamole in cancer patients. Cancer Res. 48:215–218, 1988.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. E. G. E. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. Pinedo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fox Chase Cancer Center, USA

    Robert F. Ozols

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

de Vries, E.G.E., Pinedo, H.M. (1991). Clinical implications of multidrug resistance to chemotherapy. In: Ozols, R.F. (eds) Molecular and Clinical Advances in Anticancer Drug Resistance. Cancer Treatment and Research, vol 57. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3872-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3872-1_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6726-0

  • Online ISBN: 978-1-4615-3872-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation